Clinical Trial Update: Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating two Secukinumab dosing regimens in adults with moderate-to-severe hidradenitis suppurativa has completed, and results have been poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hidradenitis Suppurativa

Drugs mentioned

• Cosentyx (secukinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Hidradenitis Suppurativa | Phase 3 | Status: COMPLETED | Results posted: 2023-08-02